CorMedix Inc. (Nasdaq: CRMD) announced today, October 20 2025, preliminary unaudited results for the third quarter of fiscal 2025. The company reported pro‑forma net revenue of more than $125 million, with DefenCath contributing over $85 million of that total. These figures represent a significant increase over the $78.8 million net sales reported in the first half of 2025 and confirm the company’s rapid commercial traction following the Melinta acquisition.
The announcement also included a $30 million operating‑synergy estimate on a go‑forward run‑rate basis before year‑end 2025, and the company raised its FY 2025 pro‑forma net revenue guidance to at least $375 million. This guidance reflects the combined revenue potential of DefenCath and Melinta’s product portfolio, and it signals continued growth momentum for the diversified specialty‑pharma platform. The updated guidance aligns with the company’s strategic objective of achieving double‑digit EPS accretion in 2026.
The preliminary results and guidance underscore CorMedix’s ability to generate robust cash flow from its flagship product while integrating Melinta’s commercial pipeline. The company noted that top‑line results for the Phase III REZZAYO study are expected in Q2 2026, which could further expand the company’s revenue base. Overall, the announcement provides investors with a clearer view of the company’s financial trajectory and reinforces the value proposition of its expanded product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.